A new Alzheimer’s treatment may help some patients, though researchers say more safety data is needed

A new study found that Eisai and Biogen’s experimental Alzheimer’s drug moderately reduced cognitive decline after a year and a half. Eisai’s 4523, The study assessing lecanemab as a treatment for people with early forms of Alzheimer’s disease was published Tuesday night by the New England Journal…

#experimentalalzheimer #alzheimer #moderatelyreduced #lecanemab #eisai #reducedcognitive #drugmoderately #disease #sanfrancisco #cognitivedecline